RecruitingPhase 2NCT04043897
Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis
Sponsor
Eugene F Yen, MD
Enrollment
10 participants
Start Date
Jun 29, 2018
Study Type
INTERVENTIONAL
Conditions
Summary
This is an open label study looking at rifaximin therapy for the treatment of microscopic (collagenous or lymphocytic) colitis.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Rifaximin 550mg for people with microscopic colitis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGRifaximin 550mg
Rifaximin 550mg
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04043897